BRAINSTORM CELL THERAPEUTICS INC. - 10-Q filing on 2021-11-15

STOCK CAPITAL (Tables)

9 Months Ended

Sep. 30, 2021

Summary of the Company's option activity

NOTE 7 – STOCK CAPITAL (Cont.):

A summary of the Company’s option activity related to options to employees and directors, and related information as of September 30, 2021, is as follows:


	For the Three months ended
	September 30, 2021
		Weighted
		average	Aggregate
	Amount of	exercise	intrinsic
	options *	price	value
		$	$
Outstanding at December 31, 2020	1,754,894	4.8869
Granted	—	—
Exercised	(1,687)	2.700
Cancelled	(482,622)	5.7222
Outstanding at September 30, 2021	1,270,585	4.5721	1,167,698
Exercisable at September 30, 2021	984,285	2.9616	1,167,698

* Represents Employee Stock Options only (not including RSUs).

Schedule of compensation expense for restricted stock is based on fair market value at the grant date


			Weighted Average
			Remaining
	Number of Shares	Weighted Average	Contractual
	of Restricted	Grant Date Fair	Term
	Stock	Value	(Years)
Nonvested as of December 31, 2020	288,081	7.71	1.10
Cancelled	35,000	13.02
Vested	126,654	6.06
Nonvested as of September 30, 2021	126,427	7.90	1.28

Schedule of total stock-based compensation expense

The total stock-based compensation expense, related to shares, options and warrants granted to employees, directors and service providers was comprised, at each period, as follows:


	Nine months ended
	September 30,
	2021		2020
Research and development	$	265	$	1,065
General and administrative		461		1,133
Total stock-based compensation expense	$	726	$	2,198